Zenkuda (tarcocimab tedromer) — NDA/BLA submission
2026
We intend to file a Biologics License Application ("BLA") in DR, RVO and wet AMD in 2026.Source filing
KOD biotech catalysts & pipeline
KODIAK SCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
Zenkuda and KSI-501 — Topline data
Sep 2026
Topline data for the one-year primary endpoint (Zenkuda and KSI-501) are expected in September 2026.Source filing
KSI-101 — Topline data
Dec 2026
Topline data from Pivotal Analysis 1 are expected in December 2026.Source filing
KSI-101 — Topline data
Q2 2027
Completion of enrollment in the second pivotal cohort evaluating 600 subjects across PEAK and PINNACLE supporting Pivotal Analysis 2 is expected in the fourth quarter of 2026, with topline data anticipated in the second quarter of 2027.Source filing